Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03832127 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients

Study acronym: Myelofludate
StatusUnknown
PhasePhase 1
Started2022-09-09
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 14, 2024 (before its estimated September 9, 2024 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-13
Trial status changed: Recruiting → Unknown
2024-06-12
Not Yet Recruiting→Recruiting Study Status, Oversight, Contacts/Locations v4
Trial statusNot Yet Recruiting→Unknown
Primary completion date2024-04-01→2024-09-09
Completion date2026-04-01→2026-09-09
Start dateestimated 2022-04-01→confirmed 2022-09-09
Study sitesdetails revised at 7 of 7 sites
2021-12-24
Study Status v3
Primary completion date2022-04-01→2024-04-01
Completion date2024-04-01→2026-04-01
Start date2019-04-01→2022-04-01
2019-03-08
Study Status v2
Re-verified, no change to tracked fields
2019-02-28
Study Status, Outcome Measures, Eligibility v1
Eligibility criteria+51 characters
[...] otential must have a serum pregnancy test (performed within 32 days before each PET scan.) AnWomen of childbearing potential must use an effective contraceptive method will also be used throughout the course of treatment (oral contraceptive, injectable, transcutaneous or implantable, ligation tubal, intrauterine device, contraceptive barrier using spermicides or vasectomy of the partner)study and for 430 weeksdays after stoppingthe last PET. Male patients (vasectomised or not) with a pregnant partner or a partner of childbearing potential must use a condom and a spermicide until 90 days after [...] [...]
Secondary endpointsdetails revised at 1 of 6 entries
2019-02-04
Original filing
The objective of this exploratory study is to evaluate, for the first time, the sensitivity of 18F-Fludarabine to the initial diagnosis of MM compared to FDG-PET and MRI. The interest of this molecule will also be investigated as part of the end-of-treatment therapeutic evaluation.
Trial Details
NCT Number NCT03832127
Lead Sponsor Nantes University Hospital
Collaborators: Cyceron
Conditions Myeloma
Enrollment 35 participants
Start Date 2022-09-09
Primary Completion 2024-09-09 (estimated)
Study Completion 2026-09-09 (estimated)
Updated on ClinicalTrials.gov 2024-06-14